REGENXBIO (NASDAQ: RGNX) has announced the appointment of Greg Ciongoli to its board of directors, effective August 25, 2026.
Mr. Ciongoli brings extensive experience in biotechnology investing, capital allocation, and corporate strategy to support the company’s next phase of growth. He is the founder and managing partner of investment firm Adiumentum Capital Management. Prior to founding Adiumentum, Mr. Ciongoli spent more than 16 years at investment company The Baupost Group, where he served as partner in public group investing and led investments in public and private companies across multiple industries and geographies. Over the course of his career, he has focused extensively on healthcare investments, corporate governance, and strategic transformation across both public and private markets. Mr. Ciongoli currently serves as chairman of the board of Atara Biotherapeutics (Nasdaq: ATRA) and is also a board member of Zymeworks (NASDAQ: ZYME).
In a statement, Curran Simpson, president and CEO of REGENXBIO, commented, “As REGENXBIO enters its next phase of growth, the board has continued its strategic succession planning process to ensure the company benefits from a complementary mix of scientific, clinical, commercial and capital markets expertise. Greg brings a combination of financial and strategic expertise that will strengthen our board as we advance our late-stage portfolio and continue our work to create life-changing treatments for patients and long-term value for our shareholders.”
Mr. Ciongoli remarked, “I am pleased to join REGENXBIO’s board during this exciting and transformational time for the company. REGENXBIO has established a leadership position in gene therapy with a differentiated platform and compelling pipeline of potential first- and best-in-class medicines. I look forward to working with the board and management team to help advance the company’s mission and strategic objectives.”
Concurrent with Mr. Ciongoli’s appointment and following years of distinguished service, Jerry Karabelas, PhD, who served as an independent director since 2015, and Jean Bennett, MD, PhD, who served as an independent director since 2021, are retiring from the board.
